Coordinated by Montpellier University Medical Center,
France, the international study IN
EXTREMIS-LASTE, representing a groundbreaking contribution to
stroke research was published today in the New England Journal of
Medicine.
MONTPELLIER, France,
May 9, 2024 /PRNewswire/ -- "LASTE"
(LArge Stroke Therapy Evaluation), a
prospective, randomized, controlled trial co-led by Professor
Vincent Costalat (neuroradiologist,
Montpellier, France) and Dr.
Caroline Arquizan (vascular neurologist, Montpellier, France), in addition to Dr. Bertrand Lapergue
(vascular neurologist, Hospital Foch, Paris, France) and Prof. Tudor Jovin
(interventional and vascular neurologist, Cooper University
Hospital, Camden, NJ, USA)
has the potential to disrupt current systems of care
involving triage and management of patients with acute stroke due
to large vessel occlusion by demonstrating that even those patients
with the largest areas of "irreversibly" damaged brain as assessed
by state-of-the-art imaging technologies still benefit from
mechanical reperfusion.
Trial of Thrombectomy for Stroke with a Large Infract of
Unrestrited Size, published in the New England Journal of
Medicine https://www.nejm.org/
Since mechanical thrombectomy, a technique that aims to restore
blood flow in stroke patients who experience sudden occlusion of a
brain artery, by removing the blockage with device-based
technologies, became standard of care in 2015, physicians selected
for such intervention only stroke patients who displayed limited
amounts of brain damage on brain imaging. This was based on the
principle that restoration of blood flow to large areas of
irreversibly damaged brain is not only futile but can also
cause additional damage due to an increased risk of bleeding in the
brain among other detrimental effects of reperfusion.
Yet, an international network of stroke centers led by the
Montpellier University Hospital investigators has proven the
opposite. The multicenter therapeutic trial "LASTE" was conducted
in France (26 centers) and
Spain (7 centers) for 3 years. The
trial aimed to select patients hitherto considered "irrecoverable"
in common practice due to unrestrictedly large areas of
irreversibly compromised brain presenting with acute stroke due to
large vessel occlusion within 7 hours of stroke onset to test the
hypothesis that reperfusion of brain tissue considered dead could
improve their outcome not only in term of survival but also in
terms of functional recovery.
IN EXTREMIS TRIALS LASTE and MOSTE are sponsored by an
Industrial unrestricted grant co-founded by 5 industrial partners
(BALT, CERENOVUS, MEDTRONIC, MICROVENTION, STRYKER).
Photo:
https://mma.prnewswire.com/media/2407575/CHU_de_Montpellier_1.jpg
Photo:
https://mma.prnewswire.com/media/2407574/CHU_de_Montpellier_2.jpg
Logo:
https://mma.prnewswire.com/media/2407576/CHU_de_Montpellier_Logo.jpg
Contacts :
v-costalat@chu-montpellier.fr
c-arquizan@chu-montpellier.fr
View original
content:https://www.prnewswire.co.uk/news-releases/a-major-advance-on-stroke-at-montpellier-university-hospital-published-in-the-new-england-journal-of-medicine-302139453.html